SELLAS Life Sciences Expert Panel Discussion: GFH009 CDK9 inhibitor in Acute Myeloid Leukemia
DATE: | May 30, 2023 |
---|---|
TIME: | 8:00 AM EDT |
LOCATION: | Virtual |
About The Event
Join us for a virtual panel discussion with SELLAS Life Sciences, featuring hematology-oncology specialists Tapan Kadia, MD (The University of Texas MD Anderson Cancer Center), Joshua Zeidner, MD (University of North Carolina Lineberger Comprehensive Cancer Center), and Omer Jamy, MD (O’Neal Comprehensive Cancer Center at the University of Alabama) who will discuss the treatment landscape for acute myeloid leukemia (AML) and the potential for GFH009 to address unmet medical needs for patients with relapsed and/or refractory AML.
GFH009 is a clinical stage small molecule, highly selective CDK9 inhibitor that SELLAS is investigating for treatment of patients with hematologic malignancies and solid tumors. SELLAS plans to commence a Phase 2a clinical trial during the second quarter of 2023 with GFH009 in combination with venetoclax and azacitidine in AML patients.
A live question and answer session will follow the formal discussion.